Cargando…

Effect of the number of dose adjustment factors on bleeding risk in patients receiving 30 mg/day edoxaban

WHAT IS KNOWN AND OBJECTIVE: Edoxaban has three dose adjustment factors (creatinine clearance, 15‐50 mL/min; body weight, 60 kg or less; and concomitant medication with potent P‐glycoprotein inhibitors) to prevent bleeding that results from elevated blood concentrations of the drug. A dose reduction...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takase, Tomoki, Ikesue, Hiroaki, Nakagawa, Haruna, Kinoshita, Megumi, Muroi, Nobuyuki, Kitai, Takeshi, Furukawa, Yutaka, Hashida, Tohru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079038/ https://www.ncbi.nlm.nih.gov/pubmed/31602680 http://dx.doi.org/10.1111/jcpt.13065

Ejemplares similares

Association between 25-hydroxyvitamin D levels and COVID-19 severity
por: Takase, Tomoki, et al.
Publicado: (2022)

Safety and efficacy evaluation of low-dose trimethoprim-sulfamethoxazole for prophylaxis of Pneumocystis pneumonia in HIV uninfected patients undergoing hemodialysis: a retrospective observational study
por: Yamashita, Kanae, et al.
Publicado: (2021)

Population pharmacokinetics and exposure–clinical outcome relationship of remdesivir major metabolite GS‐441524 in patients with moderate and severe COVID‐19
por: Tamura, Ryo, et al.
Publicado: (2023)

Evaluating the safety and efficiency of robotic dispensing systems
por: Takase, Tomoki, et al.
Publicado: (2022)

Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
por: Irie, Kei, et al.
Publicado: (2020)

Population pharmacokinetics of favipiravir in patients with COVID‐19
por: Irie, Kei, et al.
Publicado: (2021)

Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery
por: Takase, Tomoki, et al.
Publicado: (2018)

Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score–matched analysis
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Polypharmacy-associated potential contraindications of drug prescriptions in patients with primary angle closure disease in a real-world setting
por: Tanaka, Fumiaki, et al.
Publicado: (2021)

Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

Risk factors of proteinuria and potentially protective effect of renin–angiotensin system inhibitors in patients with renal cell carcinoma receiving axitinib
por: Ikesue, Hiroaki, et al.
Publicado: (2022)

Pharmacist-Urologist Collaborative Management Improves Clinical Outcomes in Patients With Castration-Resistant Prostate Cancer Receiving Enzalutamide
por: Hirabatake, Masaki, et al.
Publicado: (2022)

Safety and blood levels of daratumumab after switching from intravenous to subcutaneous administration in patients with multiple myeloma
por: Yamaoka, Kenta, et al.
Publicado: (2023)

Pharmacokinetics of Temozolomide in a Patient With Glioblastoma Undergoing Hemodialysis: A Short Communication
por: Tanaka, Fumiaki, et al.
Publicado: (2023)

Effectiveness of Pharmacist–Physician Collaborative Management for Patients With Idiopathic Pulmonary Fibrosis Receiving Pirfenidone
por: Satsuma, Yukari, et al.
Publicado: (2020)

Edoxaban: Minor bleeding: case report
Publicado: (2022)

Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
por: Tohi, Makiko, et al.
Publicado: (2023)

Evaluation of the usefulness of protocol‐based pharmacist‐facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer
por: Ikesue, Hiroaki, et al.
Publicado: (2020)

Osteonecrosis of the Jaw Caused by Denosumab in Treatment-Naïve and Pre-Treatment with Zoledronic Acid Groups: A Time-to-Onset Study Using the Japanese Adverse Drug Event Report (JADER) Database
por: Hasegawa, Shiori, et al.
Publicado: (2022)

Evaluation of pharmaceutical intervention in direct-acting antiviral agents for hepatitis C virus infected patients in an ambulatory setting: a retrospective analysis
por: Yamamoto, Haruna, et al.
Publicado: (2018)

Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
por: Ikesue, Hiroaki, et al.
Publicado: (2021)

High incidence of major bleeding with off-label use of edoxaban
por: Fukui, Rika, et al.
Publicado: (2021)

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban
por: Bosch, Floris T. M., et al.
Publicado: (2021)

Prediction and Implications of Edoxaban-Associated Bleeding in Patients after Critical Illness
por: Mikami, Ryusei, et al.
Publicado: (2023)

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study
por: Ikushima, Ippei, et al.
Publicado: (2020)

Superior mesenteric vein thrombosis treated with edoxaban
por: Hashizume, Yutaka, et al.
Publicado: (2017)

Bleeding Risk and Mortality of Edoxaban: A Pooled Meta-Analysis of Randomized Controlled Trials
por: Li, Shuang, et al.
Publicado: (2014)

Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban
por: Benz, Alexander P., et al.
Publicado: (2022)

Laboratory Test Predictors for Major Bleeding in Elderly (≥80 Years) Patients With Nonvalvular Atrial Fibrillation Treated With Edoxaban 15 mg: Sub‐Analysis of the ELDERCARE‐AF Trial
por: Mikami, Takeshi, et al.
Publicado: (2022)

The edoxaban‐M4 metabolite and measurement of edoxaban by chromogenic assays in human plasma
por: Siriez, Romain, et al.
Publicado: (2022)

Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
por: Kirchhof, Paulus, et al.
Publicado: (2022)

Association between SLCO1B1 genetic polymorphisms and bleeding risk in patients treated with edoxaban
por: Han, Ji Min, et al.
Publicado: (2023)

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model
por: Lu, Genmin, et al.
Publicado: (2018)

Managing patients taking edoxaban in dentistry
por: Curto, Adrian, et al.
Publicado: (2017)

Evaluation of anti-infective-related Clostridium difficile-associated colitis using the Japanese Adverse Drug Event Report database
por: Nakao, Satoshi, et al.
Publicado: (2020)

The Edoxaban Hokusai VTE PEDIATRICS Study: An open‐label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease
por: van Ommen, Cornelia Heleen, et al.
Publicado: (2020)

Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism
por: Said, Karim
Publicado: (2013)

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults
por: Mendell, Jeanne, et al.
Publicado: (2015)

Edoxaban in venous thromboembolism and stroke prevention: an appraisal
por: Proietti, Marco, et al.
Publicado: (2016)

Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy
por: Nitta, Kenichi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sohh2chjh6gv1c3nfm2ckkq786